Jenoptik AG / Key word(s): Change in Forecast 15.10.2014 21:19 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Annual targets are no longer attainable due to subdued demand from the machine construction, automotive and semiconductor equipment industries, as well as project postponements and more stringent export restrictions. JENOPTIK AG has revised its 2014 revenue and earnings guidance despite high order intakes. On the condition that a major international order in the Defense & Civil Systems segment can still be completed by year-end, the Executive Board is now expecting Group revenue for the current fiscal year to come in at about 600 million euros (prior year 600.3 million euros). Group operating result (EBIT) is due to total around 50 million euros (prior year 52.7 million euros). This shall apply provided that uncertainties in the defense business will not increase over the coming weeks. The prior guidance for 2014 included revenue growth of around 5 percent and Group EBIT of approximately 55 million euros. The reduced forecast for the 2014 annual targets is particularly the result of deteriorating external circumstances: On the one hand, demand from the machine construction, semiconductor equipment and automotive industries was significantly weaker in recent weeks and remained substantially below the expectations of Jenoptik, thus negatively impacting on the course of business in the Lasers & Optical Systems and Metrology segments. This situation is exacerbated by project postponements on the part of customers. On the other hand, increasingly stringent armament export restrictions issued by the German government due to the crisis in Russia and Ukraine will also result in lost revenue for the Jenoptik Group, in particular the Defense & Civil Systems segment, in the low double-digit million euro range. The Jenoptik Group will continue to consistently pursue its present strategy. Due to the adverse development of business in 2014 resulting from external circumstances, however, the Executive Board is extending its planning horizon for the Group's medium-term forecast. The company accordingly now anticipates annual revenue of around 800 million euros with an average EBIT margin of 9 to 10 percent over the market cycles, and including smaller corporate acquisitions, to be achieved in 2018, one year later than originally planned. Jenoptik will publish its figures on the first nine months of 2014 on November 12. According to preliminary estimates, Group revenue will be slightly below the level in the prior year (prior year 432.5 million euros), Group EBIT will be at last year's level (prior year 37.5 million euros). In the period covered by the report, the Group will state a substantial increase in order intake (prior year 415.4 million euros). Contact: IR, Sabine Barnekow, Phone/Fax 03641-652156/2804; www.jenoptik.de 15.10.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Jenoptik AG Carl-Zeiss-StraÃe 1 7739 Jena Germany Phone: +49 (0)364 165-0 Fax: +49 (0)364 165-2804 E-mail: ir@jenoptik.com Internet: www.jenoptik.com ISIN: DE0006229107 WKN: 622910 Indices: TecDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Jenoptik revises 2014 revenue and earnings
Top 10 Most Recent News Articles
ELEGOO's Formnext Push Tests a Broader 3D Ambition
Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...
Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal
Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...
Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge
Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...
Continue Reading
Wonder Create: Democratizing Restaurant Creation
Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...
Continue Reading
Universal Haptics Protocol May Cut Integration Friction
A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...
Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial
Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...
Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays
A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...
Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE
A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...
Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today
A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...
Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data
Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...
Continue ReadingTop 5 Most Recently Viewed Articles
TriPost Partners with Brixton Capital for Retail Expansion
Strategic Partnership between TriPost and Brixton Capital TriPost Capital Partners, a real estate private equity firm, is thrilled to announce a significant partnership with Brixton Capital for acquiring a grocery-anchored retail portfolio. This collaboration focuses on high-quality investment opportunities in rapidly developing markets. Details of the Portfolio...
Continue Reading
Archer Aviation: Pioneering A New Era in Defense Technology
Archer Aviation: A New Vision for Military Transportation When considering groundbreaking advancements in transportation, one might think of popular electric cars, but now there's a fresh contender: Archer Aviation Inc. This company stands out in the realm of electric vertical takeoff and landing aircraft (eVTOL), showcasing a vision that aligns with modern defense needs....
Continue Reading
Understanding Civil Claims for Rideshare Sexual Assault Victims
Understanding Civil Claims for Rideshare Sexual Assault Victims Victims of sexual assault during rideshare trips have avenues to seek justice and compensation. With cases involving rideshare companies like Uber and Lyft, survivors might find themselves facing challenging circumstances after an assault. Fortunately, there are legal options available for those affected by...
Continue Reading
Ramsay Santé Optimizes Debt Structure with New TLB Reppricing
Ramsay Santé Successfully Reprices Term Loans for Financial Growth Ramsay Santé recently achieved a significant milestone by repricing its €1,025 million Term Loan B4 (TLB4) and extending its €425 million Term Loan B3 (TLB3), effectively consolidating them into a new Term Loan B5. This strategic move is set to enhance their financial standing as part of their...
Continue Reading
NKGen Biotech to Present Innovative Research at Global Congress
NKGen Biotech's Exciting Announcement on Upcoming Presentation NKGen Biotech Inc. (NASDAQ: NKGN), a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge autologous and allogeneic natural killer cell therapies, has recently shared some thrilling news regarding their participation in an international event. Highlighting Neurodegenerative...
Continue Reading